Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: The phase III OVATURE multicenter randomized study

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 160-165

  Fotopoulou, C ^a,b   Vergote, I ^c   Mainwaring, P ^d   Bidzinski, M ^e   Vermorken, J B ^f   Ghamande, S A ^g   Harnett, P ^h   del Prete, S A ⁱ   Green, J A ^j   Spaczynski, M ^k   Blagden, S ^a   Gore, M ^l   Ledermann, J ^m   Kaye, S ^l   Gabra, H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MATER ADULT HOSPITAL   (Australia)

^e Hollycross Oncology Center   (Poland)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g Augusta Oncology PC   (United States)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ Bennett Cancer Center   (United States)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

^k POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Carboplatin; Ovarian cancer relapse; Phenoxodiol; Platinum resistance; Reversal; Survival

Indexed keywords

CARBOPLATIN; IDRONOXIL; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLATINUM RESISTANT OVARIAN CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

CARBOPLATIN; OVARIAN CANCER RELAPSE; PHENOXODIOL; PLATINUM RESISTANCE; REVERSAL; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; ISOFLAVONES; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84903688861     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt515     Document Type: Article

References (28)

1. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006; 367(9522): 1558-1560.
2. Colombo N, Parma G, Bocciolone L et al. Role of chemotherapy in relapsed ovarian cancer. Crit Rev Oncol Hematol 1999; 32: 221-228.
3. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
4. Del Campo JM, Roszak A, Bidzinski M et al. Yondelis Ovarian Cancer Group. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20(11): 1794-1802.
5. Gabra H. Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: teaching old dogs new tricks? Discov Med 2009; 8(42): 140-144.
6. van der Burg ME, deWit R, vanPutten WL et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002; 86: 19-25.
7. Meyer T, Nelstrop AE, Mahmoudi M et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001; 12(12): 1705-1709.
8. Sharma R, Graham J, Mitchell H et al. Extended weekly dose-dense paclitaxel/ carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009; 100(5): 707-712.
9. Cadron I, Abdulkadir L, Despierre E et al. The 'Leuven' paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. Gynecol Oncol 2013; 128(1): 34-37.
10. Piura B, Meirovitz M. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol 2005; 26(4): 386-390.
11. van der Burg ME, Vergote I, Onstenk W et al. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. Eur J Cancer 2013; 49(6): 1254-1263.
12. Alvero AB, O'Malley D, Brown D et al. Molecular mechanism of phenoxodiolinduced apoptosis in ovarian carcinoma cells. Cancer 2006; 106: 599-608.
13. Gamble JR, Xia P, Hahn CN et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006; 118(10): 2412-2420.
14. Silasi DA, Alvero AB, Rutherford TJ et al. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother 2009; 10(6): 1059-1067.
15. Kelly MG, Mor G, Husband A et al. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/ resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int J Gynecol Cancer 2011; 21(4): 633-639.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST-1.1 and CA-125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21(2): 419-423.
18. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002; 20(9): 2365-2369.
19. Ghamande S, Lele S, Marchetti D et al. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003; 13(2): 142-147.
20. Eric P-L, Felix H, Béatrice W et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012; 30(Suppl): (abstr LBA5002).
21. Morré DJ, McClain N, Wu LY et al. Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin. Mol Biotechnol 2009; 42(1): 100-109.
22. Kluger HM, McCarthy MM, Alvero AB et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007; 5: 6.
23. Burg ME, Janssen JT, Ottevanger PB et al. Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum versus weekly paclitaxel/platinum induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer. J Clin Oncol 2009; 27(Suppl): 15s (abstr: 5538).
24. Bolis G, Scarfone G, Polverino G et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22: 686-690.
25. Torfs S, Cadron I, Amant F et al. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. Eur J Cancer 2012; 48(9): 1332-1340.
26. Pignata S, Breda E, Scambia G et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 2008; 66(3): 229-236.
27. van der Burg ME, Boere IA, Berns PM. Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra. Ann Oncol 2011; 22(Suppl 8): viii33-viii39.
28. Hoekstra AV, Hurteau JA, Kirschner CV et al. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol 2009; 115(3): 377-381.